Lindahl has assisted the Swedish company Calliditas Therapeutics AB (publ) in an exclusive in-licensing of the drug Budenofalk 3mg oral capsule for the US market from the German pharmaceutical company Dr. Falk Pharma GmbH. The agreement covers all indications for the US market, excluding orphan indications outside of liver targets. Initially, Calliditas will leverage Dr. Falk’s clinical trial data and expertise in liver indications, such as autoimmune hepatitis (AIH) with a view to accelerate approval and market access. AIH is an orphan liver disease which Calliditas estimates affects about 60 – 80,000 people in the US and for which there today is no approved treatment. The total deal value amounts to 40 million EUR (approximately 428 million SEK), including future sales milestones and comes with typical royalties. Lindahl’s team consisted of Hugo Norlén, Erika Svensson, Michael Edquist, Carolin Martinez and Monica Lindström.
For more information, please see Calliditas’ press release:
https://www.calliditas.se/en/strategic-in-licensing-related-to-autoimmune-hepatitis-in-the-us-market-2914/
